Side effects
Curated, structured data for top research peptides - severity (mild / moderate / severe), frequency (common / uncommon / rare), and sources from clinical trials.
Profile
3 documented effects
BPC-157 is one of the best-tolerated regenerative peptides in the literature. Over 20 years of preclinical work documents no systemic toxicity. Most reported complaints are local — injection-site reaction and transient lethargy.
See full listProfile
3 documented effects
TB-500 has minimal documented side effects in the research literature. Goldstein and colleagues report no systemic toxicity. Most common are transient fatigue (hours post-administration) and injection-site reaction.
See full listProfile
3 documented effects
GHK-Cu is well-tolerated topically. Systemic (s.c.) doses occasionally cause transient redness around the injection site and metallic taste. At high doses there is a theoretical risk of copper imbalance — multi-month protocols warrant periodic serum ceruloplasmin.
See full listProfile
2 documented effects
KPV has an exceptionally favorable side-effect profile in the published literature. Does not activate melanocortin receptors — no pigmentation effects unlike Melanotan 2. Most common are local injection-site reactions.
See full listProfile
7 documented effects
Gastrointestinal (stomach-and-gut) side effects dominate the profile — nausea (44%), vomiting (24%), diarrhea (30%), and constipation (24%) in STEP 1. Most resolve over 8-12 weeks and are dose-dependent. Slow titration significantly reduces severity.
See full listProfile
6 documented effects
Side-effect profile resembles Semaglutide but with slightly higher nausea and diarrhea rates due to added GIP (hormone that improves insulin sensitivity) activation. SURMOUNT-1 reports transient gastrointestinal signal in 60-70% of participants during the first 12 weeks.
See full listProfile
5 documented effects
The triple mechanism — GLP-1 (hormone that reduces appetite) + GIP (hormone that improves insulin sensitivity) + glucagon — adds higher heart rate (from the glucagon component) on top of the usual gastrointestinal profile. Phase 2 reports a transient 5-7 bpm increase at higher doses.
See full listProfile
3 documented effects
Ipamorelin is known for a clean profile — selective GHRP without cortisol, prolactin, or appetite spikes (unlike GHRP-6). Most common are mild hunger at higher doses and transient water retention from GH signaling.
See full listProfile
4 documented effects
CJC-1295 (no DAC) has a favorable profile because it preserves physiological pulsatility. Most common are injection-site reactions, transient flushing, and mild hunger. The DAC version has a similar profile but with more sustained water retention due to the constant GHRH signal.
See full listProfile
5 documented effects
The FDA-approved profile includes arthralgia (joint pain, 8%), peripheral edema (5%), paresthesia (numbness/tingling, 4%) — mostly from growth-hormone signaling. Glycemic monitoring, including HbA1c (long-term blood sugar), is recommended in clinical protocols.
See full listProfile
6 documented effects
Nausea is the most common effect (40% in clinical trials) — especially the first 1-2 doses, with tolerance building afterward. Transient blood pressure elevation is documented in the Vyleesi approval.
See full listProfile
5 documented effects
Rapid IV infusion produces a flushing/chest-tightness sensation — hence the 2-4 hour slow infusion standard. Subcutaneous administration has a milder profile but more prolonged local reactions.
See full list